AbbVie has built a reputation as one of the healthcare sector’s most reliable dividend growth companies since being spun off from Abbott Laboratories in 2013.

Because of its connection to Abbott, AbbVie is often associated with the Dividend King legacy established through more than five decades of consecutive annual dividend increases.

Since becoming an independent company, AbbVie has increased its quarterly dividend from $0.40 per share to $1.73 per share, representing nearly 12% annualized dividend growth over the past 13 years.

This combination of income and consistent growth continues to make the company attractive to long-term investors seeking reliable cash flow.

Attractive Yield Meets Reasonable Valuation

Unlike many popular dividend growth stocks that have become expensive due to investor demand, AbbVie continues to trade at a valuation that many investors view as reasonable.

The stock currently offers a forward dividend yield of approximately 3%, significantly higher than the broader S&P 500 average.

At around 16 times forward earnings, AbbVie trades at a premium to some pharmaceutical peers such as Bristol Myers Squibb and Pfizer, which trade near single-digit earnings multiples.

However, the higher valuation reflects stronger earnings visibility and more favorable growth prospects compared to many competitors facing significant pipeline and patent challenges.

Moving Beyond the Humira Patent Cliff

One of the biggest concerns surrounding AbbVie in recent years was the eventual loss of exclusivity for Humira, once the world’s best-selling drug.

The arrival of biosimilar competitors beginning in 2023 led to expected declines in Humira revenue, raising questions about the company’s future growth trajectory.

AbbVie’s management anticipated this challenge years in advance and invested heavily in developing replacement growth drivers.

Those efforts are now paying off.

The company’s immunology drugs Skyrizi and Rinvoq have emerged as major growth engines, helping offset Humira’s decline while creating a new foundation for long-term revenue expansion.

Earnings Growth Outlook Remains Strong

Analysts expect AbbVie’s earnings growth to accelerate over the next several years.

After generating adjusted earnings of roughly $10 per share in 2025, projections suggest earnings could increase to approximately $14.24 per share in 2026 and $16.23 per share in 2027.

These expectations contrast sharply with some pharmaceutical competitors that are projected to experience earnings declines during the same period.

The anticipated growth reflects confidence in AbbVie’s product portfolio, commercial execution, and ability to continue expanding key therapies across multiple indications.

Dividend Growth Appears Sustainable

Rising earnings are strengthening AbbVie’s dividend coverage profile.

The company’s payout ratio is expected to decline to approximately 42%, a level generally considered healthy and sustainable for a mature pharmaceutical company.

This financial flexibility gives management room to continue rewarding shareholders through annual dividend increases while also investing in future growth opportunities.

Recent dividend increases have averaged roughly 5% to 6% annually, and strong earnings growth could support similar increases going forward.

A Rare Combination of Income and Growth

Many income-focused investors are often forced to choose between high-yield stocks with limited growth prospects or faster-growing companies that offer minimal income.

AbbVie presents a compelling middle ground.

The company offers an above-average dividend yield, a proven history of dividend increases, growing earnings, and exposure to a diversified pharmaceutical portfolio with multiple blockbuster products.

This combination helps distinguish AbbVie from many traditional healthcare and dividend stocks.

Outlook

AbbVie appears well-positioned to continue delivering both income and growth as it moves further beyond the Humira patent transition.

The success of Skyrizi and Rinvoq, combined with strong projected earnings growth and a sustainable dividend payout ratio, supports the company’s long-term investment case.

For investors seeking a blend of dividend income, earnings expansion, and reasonable valuation within the healthcare sector, AbbVie continues to stand out as one of the more compelling opportunities among large-cap dividend growth stocks.